
UBS Maintains Buy on Elevance Health, Raises Price Target to $605
UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $585 to $605.

UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $585 to $605.